<DOC>
	<DOCNO>NCT01634919</DOCNO>
	<brief_summary>•The purpose study compare performance liver biopsy non-invasive fibrosis assessment evaluate anti-fibrotic efficacy peginterferon plus ribavirin patient hepatitis C pre- post-treatment</brief_summary>
	<brief_title>Histologic Changes Noninvasive Assessment Hepatitis C Patients Treated With Peginterferon Alpha-2a Ribavirin</brief_title>
	<detailed_description>- Patients histologically advance hepatitis C receive peginterferon plus ribavirin combination therapy show 30-40 % sustain virologic response ( SVR ) rate 50 % histologic improvement . - The histologic change liver important prognosticator predict clinical outcome advance hepatitis C patient follow peginterferon-based antiviral therapy . - Although liver biopsy remain gold standard histologic assessment , several shortcoming term poor repeatability due invasiveness poor reproducibility due sample error intra- inter-observer variability . - Treatment-naïve patient chronic hepatitis C receive PEGASYS® 180 mcg weekly ribavirin twice daily 24 48 week depend genotype hepatitis C virus ( HCV ) . - All subject follow 48 week treatment cessation . - Liver biopsy do baseline end follow-up evaluation histologic response . - Noninvasive test liver fibrosis ( ARFI elastography , APRI , FIB-4 , FibroTest® , ELF test ) assess per 24 week whole study period . - The result study provide insight histo-physical link histologic change liver stiffness dynamic peginterferon alpha-2a plus ribavirin treatment patient advance hepatitis C. - Therefore , noninvasive fibrosis assessment may useful trace fibrosis outcomes patient advanced hepatitis C receive antiviral therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female subject ≥20 year age Subjects positive antiHCV Ab serum Subjects detectable HCV RNA quantitative real time polymerase chain reaction ( PCR ) ( &gt; 50 IU/mL ) Subjects without receive previous antiviral treatment Subjects undergo radiologic study ( liver ultrasonography ( USG ) , CT MRI ) exclude presence hepatocellular carcinoma ( HCC ) within last 1 year enrolment All fertile male partner childbearing age female must use reliable contraception study 3 month treatment completion Written inform consent obtain subject . History interferon ( IFN ) base therapy enrolment Positive test screen antihepatitis A virus ( HAV ) immunoglobulin M ( IgM ) Ab , HBsAg , antihepatitis D virus ( HDV ) Ab anti HIV Ab Histologically confirm liver cirrhosis ( F4 fibrosis stage ) If subject compromise liver function ( ChildPugh score &gt; 6 ) Signs symptom hepatocellular carcinoma within last 1 year enrolment History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) Women ongoing pregnancy breast feed Male partner potentially pregnant woman Neutrophil count &lt; 1,500 cells/mm3 platelet count &lt; 75,000 cells/mm3 screen Hemoglobin &lt; 11 g/dL female &lt; 12 g/dL men screen Serum creatinine level &gt; 1.5 time upper limit normal screen Evidence immunosuppressive therapy History severe psychiatric disease , especially depression . ( Severe psychiatric disease define major depression psychosis , suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Liver fibrosis</keyword>
	<keyword>ARFI ( Acoustic radiation force impulse )</keyword>
</DOC>